Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Satoshi, Kunitada"'
Autor:
Takako Shimizu, Toshihiro Oguma, Hiroshi Masumoto, Nobutoshi Sugiyama, Satoshi Kunitada, Koichiro Ogata
Publikováno v:
Thrombosis Research. 135:594-601
Introduction Since Vitamin K antagonists are associated with various limitations such as narrow therapeutic window, slow onset and offset of effect, and numerous interactions with food and drugs, new oral anticoagulants targeted to inhibit thrombin o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0157f8117fa45f187e01d7c2e9227199
https://doi.org/10.1016/j.thromres.2014.12.028
https://doi.org/10.1016/j.thromres.2014.12.028
Publikováno v:
Thrombosis Research. 129:e77-e82
Introduction Edoxaban, an oral direct factor Xa (FXa) inhibitor, is in Phase III development for prevention and treatment of thromboembolic disorders. Fondaparinux is an approved indirect FXa inhibitor. This study compared the effects of edoxaban and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0beb87de4659cb72ee34934505067018
https://doi.org/10.1016/j.thromres.2011.07.026
https://doi.org/10.1016/j.thromres.2011.07.026
Autor:
Robert P. Giugliano, Helen Kastrissios, Tomas S. Bocanegra, Simon Zhou, Michelle Green, Shashank Rohatagi, Indravadan Patel, Timothy J. Carrothers, Bruce E Dornseif, SaeHeum Song, Satoshi Kunitada, Minggao Shi, Jeanne Mendell, Daniel E. Salazar, Elliott M. Antman, Masaya Tachibana
Publikováno v:
Thrombosis and Haemostasis. 107:925-934
SummaryEdoxaban is a novel, orally available, highly specific direct inhibitor of factor Xa and is currently being developed for the treatment and prevention of venous thromboembolism and prevention of stroke and systemic embolism in patients with no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1257db9dae2118086028e4446bbb590
https://doi.org/10.1160/th11-08-0566
https://doi.org/10.1160/th11-08-0566
Autor:
Jeanne Mendell, Koichiro Ogata, Meyer Michel Samama, Stylianos Kapiotis, Michael Wolzt, Satoshi Kunitada
Publikováno v:
Thrombosis and Haemostasis. 105:1080-1090
SummaryEdoxaban, an oral direct factor Xa (FXa) inhibitor, is in phase III clinical development for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The shed blood model allows for study of activated coagulation at a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5197fb38fe8077a3ff605ca29b60dd3b
https://doi.org/10.1160/th10-11-0705
https://doi.org/10.1160/th10-11-0705
Publikováno v:
Thrombosis Research. 126:e286-e293
Introduction Edoxaban (the free base of DU-176b) is a new, oral direct Factor Xa inhibitor. This is the first study to compare the hemostatic response to edoxaban, ximelagatran, and dalteparin in healthy, elderly adults. Materials and Methods In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f9364d7784f80bd816d091a9e933c0f
https://doi.org/10.1016/j.thromres.2010.07.015
https://doi.org/10.1016/j.thromres.2010.07.015
Autor:
Satoshi Kunitada, Yoshimasa Shimoto
Publikováno v:
Japanese Journal of Thrombosis and Hemostasis. 20:527-533
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c82808a62b4ec681b362fa2cd57ecb8
https://doi.org/10.2491/jjsth.20.527
https://doi.org/10.2491/jjsth.20.527
Autor:
Dolly A. Parasrampuria, Yoshimasa Shimoto, Taro Kanamaru, Satoshi Kunitada, Ian R. Wilding, Koichiro Ogata, Alyson Connor
Publikováno v:
Journal of Clinical Pharmacology
Two studies in healthy subjects assessed the absorption of edoxaban when delivered to specific locations within the gastrointestinal tract using Enterion capsules. In study 1 (single‐dose, 4‐way crossover), 8 participants received edoxaban 60 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f172441a11d7d7531af0dc3aa67ed33a
https://pubmed.ncbi.nlm.nih.gov/25969414
https://pubmed.ncbi.nlm.nih.gov/25969414
Autor:
Juan J. Badimon, Julio I. Osende, Valentin Fuster, Daichi Shimbo, Jonathan Robbins, Julie Chen, Yoshimasa Shimoto, Satoshi Kunitada
Publikováno v:
Thrombosis and Haemostasis. 88:733-738
SummaryRecent evidence suggests that TF may play a causal role in acute coronary syndromes, and may be an important therapeutic target. Several inhibitors of TF, coagulation factors VIIa and Xa are under investigation as novel antithrombotic approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e82005207080bca71b7c3ab810a559e9
https://doi.org/10.1055/s-0037-1613294
https://doi.org/10.1055/s-0037-1613294
Autor:
Masami Fujita, Hirohisa Yamada, Takashi Inoue, Yasuko Terada, Satoshi Kunitada, Nobuyuki Murayama, Makoto Tanaka, Yasuo Ikeda
Publikováno v:
Clinical Pharmacology & Therapeutics. 66:258-264
Objective The aim of this study was to assess the tolerability, pharmacokinetic and pharmacodynamic properties of DX-9065a, a novel low-molecule specific factor Xa inhibitor in healthy male volunteers. Methods DX-9065a was intravenously administered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbea7b37f914e506560fac4cbbd46ebc
https://doi.org/10.1016/s0009-9236(99)70033-0
https://doi.org/10.1016/s0009-9236(99)70033-0
Autor:
Kazuharu Aoyagi, Yoshiyuki Morishima, Yasutaka Shinohara, Yasuko Terada, Tomoko Shibutani, Takashi Kondo, Tsuyoshi Hara, Satoshi Kunitada, Kiyoshi Tanabe
Publikováno v:
Thrombosis and Haemostasis. 81:828-34
SummaryDX-9065a is an antithrombin III (AT III)-independent and selective inhibitor of activated blood coagulation factor X (FXa). We evaluated the effects of DX-9065a and warfarin on bleeding time and blood loss in rat tail transection model and on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58476b8e3fa221ba973b036aad7242b
https://doi.org/10.1055/s-0037-1614577
https://doi.org/10.1055/s-0037-1614577